Susquehanna International Group, LLP Bio Atla, Inc. Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2024

A detailed history of Susquehanna International Group, LLP transactions in Bio Atla, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 89,183 shares of BCAB stock, worth $122,180. This represents 0.0% of its overall portfolio holdings.

Number of Shares

89,183

Previous 59,329 50.32%

Holding current value

$122,180

Previous $145,000 111.03%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$1.88 - $3.46 $56,125 - $103,294	29,854 Added 50.32%	89,183 $306,000
Q4 2023 Feb 14, 2024	SELL	$1.27 - $3.18 $84,984 - $212,796	-66,917 Reduced 53.01%	59,329 $145,000
Q3 2023 Nov 14, 2023	BUY	$1.7 - $3.07 $17,984 - $32,477	10,579 Added 9.15%	126,246 $214,000
Q2 2023 Aug 11, 2023	SELL	$2.83 - $3.87 $399,873 - $546,823	-141,298 Reduced 54.99%	115,667 $347,000
Q1 2023 May 16, 2023	BUY	$2.3 - $8.25 $67,252 - $241,230	29,240 Added 12.84%	256,965 $688,000

Q4 2022 Feb 14, 2023	BUY	$7.63 - $11.01 $1.19 Million - $1.72 Million	156,263 Added 218.67%	227,725 $1.88 Million
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $148,496 - $599,541	-50,509 Reduced 41.41%	71,462 $550,000
Q2 2022 Aug 15, 2022	BUY	$2.13 - $5.38 $37,649 - $95,096	17,676 Added 16.95%	121,971 $348,000
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $327,991 - $1.41 Million	74,884 Added 254.61%	104,295 $521,000
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $89,604 - $145,960	4,716 Added 19.1%	29,411 $577,000
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $470,039 - $698,352	15,966 Added 182.91%	24,695 $727,000
Q2 2021 Aug 11, 2021	BUY	$38.07 - $56.17 $332,313 - $490,307	8,729 New	8,729 $370,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $49.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Bio Atla, Inc. Transaction History